Zone Leader: Eric J. Woolf


Eric WoolfDr. Woolf currently directs the Clinical Regulated Bioanalysis Group of Merck Research Laboratories, West Point, PA. He received his B.A. in Chemistry from LaSalle College in 1982, and a Ph.D. in Analytical Chemistry from Seton Hall University in 1986. From 1986 to 1990 he was a member of the Drug Metabolism/Pharmacokinetics Dept. of Berlex Laboratories. He joined Merck Research Laboratories in 1990 as a research fellow. Dr. Woolf and his group have supported numerous clinical development projects that have led to the successful registration of Merck compounds. Since 1986, he has authored or co-authored over 50 research papers pertaining to bioanalysis and pharmacokinetics. His major research interests include the utilization of novel HPLC approaches in bioanalysis and the bioanalysis of unstable compounds.

 

What three things would you take if you were stranded on a desert island?

  • A satellite phone with solar charger
  • a flint and striker
  • a case of duct tape

If you weren’t a bioanalysts what would you be?

  • Either a computer repair person or a genealogist

What is your favorite city?

  • London

Why have you decided to become a Zone Leader?

To stay connected with the bioanalytical community.


Journal articles from BioanalysisPanel discussions
2016 White Paper on recent issues in bioanalysis: focus on biomarker assay validation (BAV) (Part 1 – small molecules, peptides and small molecule biomarkers by LCMS)

Issues facing the bioanalytical community: summary of round table discussions

2015 White Paper on recent issues in bioanalysis: focus on new technologies and biomarkers (Part 1 – small molecules by LCMS)

A device for dried blood microsampling in quantitative bioanalysis: overcoming the issues associated blood hematocrit

Direct comparison of radioimmunoassay and LC–MS/MS for PK assessment of insulin glargine in clinical development

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 2 – hybrid LBA/LCMS, ELN & regulatory agencies’ input)

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 3 – LBA and immunogenicity)

2014 White Paper on recent issues in bioanalysis: a full immersion in bioanalysis (Part 1 – small molecules by LCMS)

2013 White Paper on recent issues in bioanalysis: ‘hybrid’ – the best of LBA and LCMS

Merck’s perspective on the implementation of dried blood spot technology in clinical drug development – why, when and how

2012 White Paper on Recent Issues in Bioanalysis and Alignment of Multiple Guidelines

2011 White Paper on Recent Issues in Bioanalysis and Regulatory Findings from Audits and Inspections

2010 White Paper on Recent Issues in Regulated Bioanalysis & Global Harmonization of Bioanalytical Guidance

Building the Global Bioanalysis Consortium – working towards a functional globally acceptable and harmonized guideline on bioanalytical method validation

Back to Zone Leaders